Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

Lung cancer is classified into two major categories: non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancer cases, and small-cell lung cancer (SCLC), which accounts for the ...

In this analysis from the phase 3 EMPOWER‐Lung 1 study, researchers reported on quality of life in patients with advanced non‐small cell lung cancer and PD-L1 expression of 50% or more.

The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the upcoming ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...